Dr. Natarajan Ranganathan (Dr. Rangan) is Managing Director (R&D) and key founder of Kibow Biotech Inc., a 21-year-old biotechnology company specializing in the clinical utility of probiotics/prebiotics towards Chronic Kidney Disease (CKD) and related applications. Dr. Ranganathan has significant professional expertise and knowledge related to the fields of Gut Microbiome, Dysbiosis, and its stabilization with Probiotics and Prebiotics. Under his scientific leadership, Kibow was awarded, two consecutive Small Business Innovation Research (SBIR) fast-track grants from the National Institute of Diabetes, Digestive, and Kidney (NIDDK) Diseases – NIH and additional funding from the United States Agency for International Aid (USAID) totaling $3.0 million. Additionally, the company received a grant of quarter million dollars under the US Government’s Qualifying Therapeutic Discovery Project, or QTDP, program.